Invus is an evergreen equity investment firm that focuses on empowering owner-managers to transform their industries through a long-term investment horizon. The firm invests across a broad range of sectors, including biotech, AI/ML, FinTech, consumer goods, and software, aiming for sustainable value creation by providing capital, strategic advice, and the freedom to take risks.
Portfolio
15
Fund Size
$10B
Top Stage
Series A
Last 12 Mo
4
Team
PA
Philippe Amouyal
Managing Director
Stage Distribution
Portfolio
15 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Triana Biomedicines | Series B | $120M | Dec 2025 |
| Bambusa Therapeutics | Series A | — | Nov 2025 |
| One Biosciences | Series A | $15M | Jul 2025 |
| Aive | Series A | $12M | Jun 2025 |
| Bambusa Therapeutics | Series A | — | Feb 2025 |
| Ottimo Pharma | Series A | $140M | Dec 2024 |
| PrognomiQ | Series D | $34M | Nov 2024 |
| Triveni Bio Inc. | Series B | $115M | Oct 2024 |
| KNIME | Series B | $30M | Aug 2024 |
| Exsilio Therapeutics | Series A | $82M | Jun 2024 |
| Flare Therapeutics Inc. | Series B | $123M | Mar 2023 |
| Hemab Therapeutics | Series B | $135M | Feb 2023 |
| ElevateBio | Series B | $170M | Mar 2020 |
| Olive | Series A | $15M | — |
| The Curious AI Company | Seed | $1M | — |
Top Co-Investors
RA Capital Management4 shared
Redmile Group4 shared
OrbiMed3 shared
Novartis Venture Fund2 shared
Janus Henderson Investors2 shared
Deep Track Capital2 shared
Atlas Venture2 shared
Surveyor Capital2 shared
RTW Investments1 shared
Catalio Capital Management1 shared
Casdin Capital1 shared
Eventide Asset Management1 shared
Nextech Invest1 shared
Third Rock Ventures1 shared
Eli Lilly and Company1 shared
Pavilion Capital1 shared
Delos Capital1 shared
Insight Partners1 shared
Innovation Endeavors1 shared
Arc1 shared
Last updated: 3 March 2026